Shi-Ming Lin

Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization

I. Sheen, Yi-Cheng Chen, K. Lui, 2017, Journal of viral hepatitis.

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

D. Tsan, Eric Yi-Liang Shen, Po-Ting Lin, 2024, The oncologist.

Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.

I. Sheen, W. Jeng, W. Teng, 2024, Journal of the Formosan Medical Association = Taiwan yi zhi.

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

H. Kosaka, A. Soyama, Ying-Chun Shen, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adding nutritional status to the original BCLC stage improves mortality prediction for hepatocellular carcinoma patients in HBV-endemic regions.

Chun-Yi Tsai, Chen-Chun Lin, W. Teng, 2023, American journal of cancer research.

Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Shi-Ming Lin, Wei Teng, Hung-Wei Wang, 2024, Liver cancer.